Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?
Adnan
A
Kastrati
Robert A
RA
Byrne
Stefanie
S
Schulz
D023903:Coronary Restenosis / Q000517:prevention & control*; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058924:Thienopyridines / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D058924:Thienopyridines; C489443:zotarolimus; D020123:Sirolimus